Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study

Hidehiro Itonaga, Masako Iwanaga, Kazunari Aoki, Jun Aoki, Ken Ishiyama, Takayuki Ishikawa, Toru Sakura, Takahiro Fukuda, Yuho Najima, Toshiaki Yujiri, Takehiko Mori, Mineo Kurokawa, Yuichiro Nawa, Naoyuki Uchida, Yoshihisa Morishita, Hisako Hashimoto, Tetsuya Eto, Makoto Hirokawa, Yasuo Morishima, Tokiko Nagamura-InoueYoshiko Atsuta, Yasushi Miyazaki

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a therapeutic option that may lead to improved outcomes in patients with chronic myelomonocytic leukemia (CMML). However, few studies have examined the impact of the grade of graft-versus-host disease (GVHD) on post-transplant outcomes for CMML. We retrospectively analyzed the outcomes of 141 patients with CMML who underwent allo-HSCT between 1987 and 2010, and achieved neutrophil engraftment. The effects of acute GVHD (aGVHD) or chronic GVHD (cGVHD) on overall survival (OS), leukemia-associated mortality (LAM), and transplant-related mortality were evaluated by hazards regression models, in which the onset date of aGVHD or cGVHD was treated as a time-dependent covariate. Grade I aGVHD was associated with better OS and lower LAM (P = 0.042, P = 0.033, respectively) than no GVHD in univariate analyses, but not in the multivariate analyses. The multivariate analyses demonstrated that extensive cGVHD significantly associated with better OS (Hazard Ratio [HR] 0.35 [95% confidence intervals (CI), 0.16-0.74]; P = 0.007) and lower LAM (HR 0.36 [95% CI, 0.14-0.92]; P = 0.033) in patients who were not in complete remission at transplantation. In conclusion, the occurrence of cGVHD may be an important factor affecting the outcomes of CMML patients who received transplantation.

Original languageEnglish
Pages (from-to)48-55
Number of pages8
JournalLeukemia Research
Volume41
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Leukemia, Myelomonocytic, Chronic
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Retrospective Studies
Leukemia
Mortality
Survival
Multivariate Analysis
Transplantation
Confidence Intervals
Transplants
Proportional Hazards Models
Neutrophils

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Chronic myelomonocytic leukemia
  • Graft-versus-host disease
  • Graft-versus-leukemia effect

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia : A nationwide retrospective study. / Itonaga, Hidehiro; Iwanaga, Masako; Aoki, Kazunari; Aoki, Jun; Ishiyama, Ken; Ishikawa, Takayuki; Sakura, Toru; Fukuda, Takahiro; Najima, Yuho; Yujiri, Toshiaki; Mori, Takehiko; Kurokawa, Mineo; Nawa, Yuichiro; Uchida, Naoyuki; Morishita, Yoshihisa; Hashimoto, Hisako; Eto, Tetsuya; Hirokawa, Makoto; Morishima, Yasuo; Nagamura-Inoue, Tokiko; Atsuta, Yoshiko; Miyazaki, Yasushi.

In: Leukemia Research, Vol. 41, 01.02.2016, p. 48-55.

Research output: Contribution to journalArticle

Itonaga, H, Iwanaga, M, Aoki, K, Aoki, J, Ishiyama, K, Ishikawa, T, Sakura, T, Fukuda, T, Najima, Y, Yujiri, T, Mori, T, Kurokawa, M, Nawa, Y, Uchida, N, Morishita, Y, Hashimoto, H, Eto, T, Hirokawa, M, Morishima, Y, Nagamura-Inoue, T, Atsuta, Y & Miyazaki, Y 2016, 'Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study', Leukemia Research, vol. 41, pp. 48-55. https://doi.org/10.1016/j.leukres.2015.12.009
Itonaga, Hidehiro ; Iwanaga, Masako ; Aoki, Kazunari ; Aoki, Jun ; Ishiyama, Ken ; Ishikawa, Takayuki ; Sakura, Toru ; Fukuda, Takahiro ; Najima, Yuho ; Yujiri, Toshiaki ; Mori, Takehiko ; Kurokawa, Mineo ; Nawa, Yuichiro ; Uchida, Naoyuki ; Morishita, Yoshihisa ; Hashimoto, Hisako ; Eto, Tetsuya ; Hirokawa, Makoto ; Morishima, Yasuo ; Nagamura-Inoue, Tokiko ; Atsuta, Yoshiko ; Miyazaki, Yasushi. / Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia : A nationwide retrospective study. In: Leukemia Research. 2016 ; Vol. 41. pp. 48-55.
@article{c9a5bf9da1f24b4c84a012fffbd042b6,
title = "Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a therapeutic option that may lead to improved outcomes in patients with chronic myelomonocytic leukemia (CMML). However, few studies have examined the impact of the grade of graft-versus-host disease (GVHD) on post-transplant outcomes for CMML. We retrospectively analyzed the outcomes of 141 patients with CMML who underwent allo-HSCT between 1987 and 2010, and achieved neutrophil engraftment. The effects of acute GVHD (aGVHD) or chronic GVHD (cGVHD) on overall survival (OS), leukemia-associated mortality (LAM), and transplant-related mortality were evaluated by hazards regression models, in which the onset date of aGVHD or cGVHD was treated as a time-dependent covariate. Grade I aGVHD was associated with better OS and lower LAM (P = 0.042, P = 0.033, respectively) than no GVHD in univariate analyses, but not in the multivariate analyses. The multivariate analyses demonstrated that extensive cGVHD significantly associated with better OS (Hazard Ratio [HR] 0.35 [95{\%} confidence intervals (CI), 0.16-0.74]; P = 0.007) and lower LAM (HR 0.36 [95{\%} CI, 0.14-0.92]; P = 0.033) in patients who were not in complete remission at transplantation. In conclusion, the occurrence of cGVHD may be an important factor affecting the outcomes of CMML patients who received transplantation.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Chronic myelomonocytic leukemia, Graft-versus-host disease, Graft-versus-leukemia effect",
author = "Hidehiro Itonaga and Masako Iwanaga and Kazunari Aoki and Jun Aoki and Ken Ishiyama and Takayuki Ishikawa and Toru Sakura and Takahiro Fukuda and Yuho Najima and Toshiaki Yujiri and Takehiko Mori and Mineo Kurokawa and Yuichiro Nawa and Naoyuki Uchida and Yoshihisa Morishita and Hisako Hashimoto and Tetsuya Eto and Makoto Hirokawa and Yasuo Morishima and Tokiko Nagamura-Inoue and Yoshiko Atsuta and Yasushi Miyazaki",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.leukres.2015.12.009",
language = "English",
volume = "41",
pages = "48--55",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia

T2 - A nationwide retrospective study

AU - Itonaga, Hidehiro

AU - Iwanaga, Masako

AU - Aoki, Kazunari

AU - Aoki, Jun

AU - Ishiyama, Ken

AU - Ishikawa, Takayuki

AU - Sakura, Toru

AU - Fukuda, Takahiro

AU - Najima, Yuho

AU - Yujiri, Toshiaki

AU - Mori, Takehiko

AU - Kurokawa, Mineo

AU - Nawa, Yuichiro

AU - Uchida, Naoyuki

AU - Morishita, Yoshihisa

AU - Hashimoto, Hisako

AU - Eto, Tetsuya

AU - Hirokawa, Makoto

AU - Morishima, Yasuo

AU - Nagamura-Inoue, Tokiko

AU - Atsuta, Yoshiko

AU - Miyazaki, Yasushi

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a therapeutic option that may lead to improved outcomes in patients with chronic myelomonocytic leukemia (CMML). However, few studies have examined the impact of the grade of graft-versus-host disease (GVHD) on post-transplant outcomes for CMML. We retrospectively analyzed the outcomes of 141 patients with CMML who underwent allo-HSCT between 1987 and 2010, and achieved neutrophil engraftment. The effects of acute GVHD (aGVHD) or chronic GVHD (cGVHD) on overall survival (OS), leukemia-associated mortality (LAM), and transplant-related mortality were evaluated by hazards regression models, in which the onset date of aGVHD or cGVHD was treated as a time-dependent covariate. Grade I aGVHD was associated with better OS and lower LAM (P = 0.042, P = 0.033, respectively) than no GVHD in univariate analyses, but not in the multivariate analyses. The multivariate analyses demonstrated that extensive cGVHD significantly associated with better OS (Hazard Ratio [HR] 0.35 [95% confidence intervals (CI), 0.16-0.74]; P = 0.007) and lower LAM (HR 0.36 [95% CI, 0.14-0.92]; P = 0.033) in patients who were not in complete remission at transplantation. In conclusion, the occurrence of cGVHD may be an important factor affecting the outcomes of CMML patients who received transplantation.

AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a therapeutic option that may lead to improved outcomes in patients with chronic myelomonocytic leukemia (CMML). However, few studies have examined the impact of the grade of graft-versus-host disease (GVHD) on post-transplant outcomes for CMML. We retrospectively analyzed the outcomes of 141 patients with CMML who underwent allo-HSCT between 1987 and 2010, and achieved neutrophil engraftment. The effects of acute GVHD (aGVHD) or chronic GVHD (cGVHD) on overall survival (OS), leukemia-associated mortality (LAM), and transplant-related mortality were evaluated by hazards regression models, in which the onset date of aGVHD or cGVHD was treated as a time-dependent covariate. Grade I aGVHD was associated with better OS and lower LAM (P = 0.042, P = 0.033, respectively) than no GVHD in univariate analyses, but not in the multivariate analyses. The multivariate analyses demonstrated that extensive cGVHD significantly associated with better OS (Hazard Ratio [HR] 0.35 [95% confidence intervals (CI), 0.16-0.74]; P = 0.007) and lower LAM (HR 0.36 [95% CI, 0.14-0.92]; P = 0.033) in patients who were not in complete remission at transplantation. In conclusion, the occurrence of cGVHD may be an important factor affecting the outcomes of CMML patients who received transplantation.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Chronic myelomonocytic leukemia

KW - Graft-versus-host disease

KW - Graft-versus-leukemia effect

UR - http://www.scopus.com/inward/record.url?scp=84957844673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957844673&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2015.12.009

DO - 10.1016/j.leukres.2015.12.009

M3 - Article

C2 - 26754557

AN - SCOPUS:84957844673

VL - 41

SP - 48

EP - 55

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -